Leukemia's Next Top Model? Syngeneic Models to Advance Adoptive Cellular Therapy

Area of Science:

• Immunology
• Oncology
• Translational Medicine

Background:

• Adoptive cell therapies (ACT) show promise for B-cell malignancies but face challenges from immune dysregulation and the leukemia microenvironment.
• Current human xenograft models inadequately assess the impact of the immunosuppressive leukemia microenvironment on ACT efficacy.
• Preclinical modeling is crucial for understanding and overcoming barriers to successful ACT in leukemia.

Purpose of the Study:

• To review the immunosuppressive features of the leukemia microenvironment.
• To discuss the utility of preclinical models in predicting ACT-associated toxicities and dysfunction.
• To explore the application of syngeneic mouse models in advancing ACT for leukemia treatment.

Main Methods:

• Review of literature on adoptive cell therapies (ACT) for hematological malignancies.
• Analysis of the immunosuppressive leukemia microenvironment.
• Examination of syngeneic mouse models for ACT preclinical studies.
• Evaluation of cytotoxic T lymphocytes, T cell receptor transgenics, and chimeric antigen receptors in syngeneic models.

Main Results:

• Syngeneic models provide a viable alternative to xenografts, maintaining a matched immune system and tumor microenvironment.
• These models allow for the study of complex immune interactions, including T cell-based therapies.
• Syngeneic models aid in predicting potential toxicities and dysfunctions associated with ACT.

Conclusions:

• Syngeneic mouse models are essential for advancing ACT by accurately reflecting the leukemia microenvironment.
• These models facilitate the prediction of ACT toxicities and immune-related adverse events.
• Further utilization of syngeneic models will improve the development and efficacy of ACT for leukemia.